Genmab — Juni 2022

Bulder

so this is a new biontec collaboration drug. What do we know about targets?

Bulder

Is it hex or duo?

Solsen

I cant find anything. I belive Biontech have had some info latest.

E_L

all good questions

E_L

the only guess i can make is that it could be a hexabody, as Biointech (mistakenly?) put a reference to a hexabody in one of their presentations a while ago

Solsen

Undisclosed target - looks like

Solsen

Kig med den 29. juni så kan det være vi kan spotte target https://investors.biontech.de/news-releases/news-release-details/biontech-host-first-edition-innovation-series-diversified

ProinvestorNEWS

Tirsdagens aktier: SAS i hopla - defensive aktier tyngede rødt C25
https://www.proinvestor.com/investornyt/843585/tirsdagens-aktier-sas-i-hopla-defensive-aktier-tyngede-rodt-c25

ProinvestorNEWS

USA/middag: Tech presser aktierne ned - energi igen i front
https://www.proinvestor.com/investornyt/843619/usa-middag-tech-presser-aktierne-ned-energi-igen-i-front

ProinvestorNEWS

USA/lukning: Solide plusser vendt til tunge minusser
https://www.proinvestor.com/investornyt/843702/usa-lukning-solide-plusser-vendt-til-tunge-minusser

Helge_LarsenPI-redaktør

God morgen.

Stroka

God morgen.

E_L

https://jeccr.biomedcentral.com/articles/10.1186/s13046-022-02421-2 Expanding anti-CD38 immunotherapy for lymphoid malignancies

Sukkeralf

https://endpts.com/years-after-linking-arms-with-bristol-myers-and-both-mercks-sutro-finds-its-latest-partner-in-tokyo/

Sukkeralf

Hov det link skulle i bio-chatten

ProinvestorNEWS

Aktier/middag: Plus til Mærsk i nervøs og tynd handel
https://www.proinvestor.com/investornyt/843868/aktier-middag-plus-til-maersk-i-nervos-og-tynd-handel

Sukkeralf

Spændende at læse denne, når det endelige view kommer ud:

Sukkeralf

Just a moment...

(firstwordpharma.com)

E_L

can't see anything about GEN1053 in the BionTech presentation, but they will discuss GEN1046 (BNT311) and
GEN1042 (BNT312) https://investors.biontech.de/static-files/edee73bd-1620-4f51-a419-7ce7782ffa0f

E_L

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-announces-us-fda-breakthrough-therapy-designation-granted-for-talquetamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-301577835.html